Chicago, ILNCT07604272Now EnrollingIRB Ready

Inguinal Hernia Unilateral Clinical Trial in Chicago, IL

Access cutting-edge inguinal hernia unilateral treatment through this phase 1 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access inguinal hernia unilateral specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related inguinal hernia unilateral treatment provided free

Apply for This Chicago Location

Check if you qualify for this inguinal hernia unilateral clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Inguinal Hernia Unilateral Study in Chicago

This is a prospective, single-center, three-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive fulvestrant 250 mg intramuscularly, fulvestrant 500 mg intramuscularly, or letrozole 5 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Age ≥ 50 years at time of enrollment
Symptomatic unilateral inguinal hernia confirmed on physical examination
Hernia visible / confirmed on groin ultrasound
Non-recurrent inguinal hernia (primary hernia only)
Willing and able to provide written informed consent
Able and willing to comply with all protocol-required visits, laboratory assessments, imaging, and follow-up
Willing to use contraception and avoid fathering a child during study participation and for 12 months after last dose
Willing to be counseled regarding vitamin D and calcium supplementation Bone safety mitigation measure per PIND response.

Exclusion Criteria

Hernia Characteristics
Scrotal hernia (any)
Bilateral inguinal hernia
Recurrent inguinal hernia (prior repair at same site) Renal \& Hepatic
Clinically significant renal dysfunction judged by investigator to increase study risk
Clinically significant hepatic dysfunction at baseline Hematologic ■ Clinically significant baseline hematologic abnormality (including elevated hematocrit or polycythemia) Urologic / Prostate
Symptomatic benign prostatic hyperplasia (BPH) requiring active medical or procedural treatment
Clinically significant untreated prostate disease Skeletal / Bone
Baseline osteoporosis (T-score ≤ -2.5 on DEXA at any site)
Recent fragility fracture (within prior 12 months or as judged by investigator)
Other clinically significant skeletal vulnerability judged to increase risk from estrogen suppression Immunosuppression ■ Active immunosuppression (e.g., systemic corticosteroids, biologic agents, post-transplant regimens) Psychiatric ■ Unstable or uncontrolled psychiatric illness that, in the investigator's judgment, would interfere with safe study participation Reproductive / Fertility ■ Actively pursuing fertility or planning conception during study participation Prior / Concomitant Therapy
Current use of androgen replacement therapy, exogenous estrogen, or other endocrine-active agents that would confound study interpretation
Prior or current use of aromatase inhibitor or selective estrogen receptor modulator / degrader within 6 months of enrollment General ■ Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would place the participant at unacceptable risk or compromise study integrity

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07604272) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Inguinal Hernia Unilateral Treatment Options in Chicago, IL

If you're searching for inguinal hernia unilateral treatment options in Chicago, IL, this clinical trial (NCT07604272) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced inguinal hernia unilateral specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all inguinal hernia unilateral clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Chicago, IL

See all rheumatoid arthritis clinical trials recruiting in Chicago — not just this study.

Browse Rheumatoid Arthritis Trials in Chicago →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL